Kogavant (Ticagrelor)

Ticagrelor works by reversibly binding to the P2Y12 ADP receptor on platelets. This blocks ADP‑mediated platelet activation, preventing fibrinogen from linking platelets together, which in turn inhibits platelet aggregation and reduces the formation of arterial clots that can cause heart attacks or strokes.

The specific dose of Kogavant is determined by the prescribing clinician based on the individual patient's clinical condition, renal and hepatic function, and concomitant medications. Healthcare professionals follow local prescribing guidelines and adjust the regimen as needed for safety and efficacy.

Safety data for ticagrelor in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Clinicians typically avoid prescribing Kogavant to pregnant or nursing women unless no suitable alternatives exist.

To order Kogavant, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kogavant (ticagrelor) differs from clopidogrel, another P2Y12 inhibitor, by providing more rapid and consistent platelet inhibition without requiring metabolic activation. This can result in a quicker onset of action and potentially greater efficacy, though both agents share similar bleeding risk profiles.

Kogavant tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Kogavant is taken orally as a tablet. Patients should swallow the tablet whole with water, with or without food, as directed by their healthcare provider. The exact timing relative to meals may be specified by the prescriber.

The most serious risks include severe or life‑threatening bleeding such as intracranial hemorrhage, hypersensitivity reactions like rash or anaphylaxis, and significant elevations in liver enzymes. Patients should seek immediate medical attention if they experience unusual bleeding, breathing difficulties, or signs of an allergic reaction.

Kogavant should be avoided in patients with active pathological bleeding, a history of intracranial hemorrhage, severe hepatic impairment, or known hypersensitivity to ticagrelor or any of its excipients. Caution is also advised for individuals on strong CYP3A4 inhibitors or those with uncontrolled hypertension.